Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Story continues below

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On October 20, 2017, the Board of Directors (the "Board") of Juno Therapeutics, Inc. (“Juno”), upon recommendation of the Compensation Committee of the Board, granted a restricted stock award for 35,893 shares to each of our executive officers, Hans E. Bishop, Sunil Agarwal, Robert Azelby, Bernard J. Cassidy, and Steven D. Harr, under the Company's 2014 Equity Incentive Plan. The restricted stock awards will become eligible to vest based on the achievement of certain performance goals as follows, subject to the executive remaining a service provider to Juno on the applicable vesting date:

Up to 21,535 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the "FDA") of JCAR017 in any indication within certain designated timeframes (the "JCAR017 Milestone").

50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement.

The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement.

Up to 14,358 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes.

The foregoing description of the restricted stock awards is not complete and is qualified in its entirety by reference to the full text of the form of restricted stock agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K, and the 2014 Equity Incentive Plan, which was filed as Exhibit 10.22 to Juno's Registration Statement of Form S-1/A on December 9, 2014, both of which are incorporated herein by reference.

Item 5.02

Financial Statements and Exhibits.

(d) Exhibits


Juno Therapeutics, Inc. Exhibit
EX-10.1 2 exhibit101.htm EXHIBIT 10.1 Exhibit Exhibit 10.1JUNO THERAPEUTICS,…
To view the full exhibit click here

About Juno Therapeutics, Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

An ad to help with our costs